Article Sidebar
Published:
Aug 14, 2017Article Details
Copyright remains in the Author’s name. The work is licensed under a Creative Commons Attribution - Noncommercial Works License. Authors are required to complete and sign an Author Agreement form that outlines Author and Publisher rights and terms of publication. The Agreement form should be uploaded along with other submissions files and any submission will be considered incomplete without it [forthcoming].
Material submitted for publication in the SAMJ is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement. The SAMJ does not hold itself responsible for statements made by the authors.
Previously published images
If an image/figure has been previously published, permission to reproduce or alter it must be obtained by the authors from the original publisher and the figure legend must give full credit to the original source. This credit should be accompanied by a letter indicating that permission to reproduce the image has been granted to the author/s. This letter should be uploaded as a supplementary file during submission.
Main Article Content
Serum beta-2-microglobulin in the differential diagnosis of monoclonal gammopathies
Abstract
Serum beta-2-microglobulin (B2m) concentrations were determined in 43 southern African black patients with multiple myeloma (MM), in 130 black patients with monoclonal gammopathy of undetermined significance (MGUS) and in 70 control subjects. The results showed median values for serum B2m in patients with MM, MGUS and the control group to be 8,10 mg/l, 3,05 mg/l, and 2,35 mg/l, respectively; these values differed significantly from one another (P< 0,01), even when patients with normal renal function (serum creatinine value < 110 μmol/l) were considered separately. The median serum B2m concentration for IgG MM (22 cases) was 4,3 mg/l, for IgA MM (8 cases) 7,3 mg/l, and 24,2 mg/l for Bence Jones MM (12 cases). These differences were also significant (P = 0,001), but not in the restricted group of MM patients with normal renal function. In the 43 MM patients serum B2m concentrations had a significant positive correlation with serum creatinine (r = 0,706; P < 0,005) and a significant negative correlation with haemoglobin values (r =-0,459; P = 0,006). In 28 MM patients with normal renal function, serum B2m values had a significant negative correlation with serum albumin (r = -0,602, P = 0,003). Sixty-five per cent of the 43 MM patients and 18,5% of the MGUS patients had raised serum B2m values (> 4,7 mgl/). An optimum cut-off value for serum B2m of 6,9 mg/l for differentiating MM from MGUS was determined using a classification rule. Despite lacking specificity, serum B2m measurement was useful in differentiating MM from MGUS, and was the best second choice variable in relation to serum albumin and haemoglobin in patients with normal renal function.
